Not medical advice. PT-141 is a research compound. This guide does not provide dosing, diagnosis, therapy recommendations, or claims about effects in humans.
PT-141 is listed in our catalogue under “Tanning / Libido.” In scientific publications it is discussed in technical language; this page translates the general themes into everyday wording while staying faithful to research-only framing.
One-paragraph overview from our research datasheet — still scientific, but faster to read than the full mechanism list below.
Bremelanotide (PT-141) FDA-approved MC4R agonist for HSDD activates hypothalamic sexual arousal pathways via central melanocortin signaling. t½ 2.7 hours SC.
Peer-reviewed literature typically discusses PT-141 in specific experimental settings. The points below reflect how the scientific community frames this compound—not as health claims, but as the research questions being asked.
Research vs. personal use: Literature describes experiments in controlled lab and animal models. This is distinct from any real-world use; our products are for laboratory research only.
These peptides are studied mainly for how they interact with melanocortin receptors and pigmentation biology. That research is separate from human “tanning products” and stays in controlled scientific contexts.
Our datasheet lists mechanistic themes observed in preclinical work. These are research endpoints, not health claims. They help scientists understand and compare pathways.
Storage requirements: Lyophilised powder: store in freezer (−20 °C). Reconstituted: refrigerate 1–6 °C, away from sunlight. Use within the validated stability window for the specific batch and formulation. · Learn best practices in our detailed storage guide.
Research dosing context: Literature typically discusses 1.75 mg subcutaneously (FDA-approved dose) · As needed, at least 45 minutes before anticipated sexual activity. Maximum one dose per 24 hours, ≤8 doses per month · SC t½ = 2.7 hr (range 1.9-4.0 hr). Tmax ~1 hr. Vd = 25.0 L. CL = 6.5 L/hr. Protein binding 21%. Excretion: 64.8% urine, 22.8% feces. Most common adverse effect: nausea (40%). Biological effect duration 4-8 hr exceeds plasma half-life. Available as 1.75 mg/0.3 mL autoinjector pen (Vyleesi).
Preparation steps: Follow our detailed reconstitution guide, use the calculator tool for volume confirmation, and always verify purity with the COA reading guide.
PT-141 (bremelanotide) is a cyclic melanocortin-receptor agonist peptide that acts centrally on MC4R arousal pathways. It is the molecule approved as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women. New-U's PT-141 is research-grade material supplied for laboratory use only — not the approved drug and not for human use.
In research and clinical studies PT-141 activates hypothalamic MC4R circuits involved in sexual motivation/arousal — acting on the brain rather than on peripheral blood flow. These are findings for the molecule; New-U supplies research-grade PT-141 for laboratory research only and implies no human effect.
The approved drug (bremelanotide / Vyleesi) is indicated for hypoactive sexual desire disorder in premenopausal women, acting on central MC4R arousal pathways. That is the clinical product; New-U supplies research-grade PT-141 strictly for laboratory research, not for human use.
Published pharmacology describes a relatively short plasma half-life with a functional window of several hours in studies of the molecule. This is reported research context only — not human-use dosing guidance. New-U supplies PT-141 for laboratory research only.
The pharmaceutical bremelanotide (Vyleesi) is FDA-approved for HSDD in premenopausal women. That approval applies to the finished prescription drug — NOT to research-grade material. New-U's PT-141 is an unapproved research powder supplied for laboratory research only.
PDE-5 inhibitors like Viagra work peripherally - they relax smooth muscle and improve blood flow to the genital tissue, which helps with the mechanics of erection. They do nothing about desire or arousal. PT-141 works centrally in the brain, activating hypothalamic MC4R circuits that generate sexual motivation. The two classes target completely different steps and can theoretically even be used together.
PT-141 is essentially an active metabolite of MT-2 with a free carboxylic acid at the C-terminus instead of an amide. That single change shifts selectivity toward MC4R-mediated arousal and away from the broader MC1/3/4/5 activity of MT-2 - keeping the sexual effects while reducing pigmentation, nausea, and facial flushing.
MC4R is expressed in multiple hypothalamic nuclei including the ones that control nausea and appetite, so central MC4R activation inevitably produces some nausea as a dose-dependent effect. In the Vyleesi clinical trials, around 40% of subjects experienced some nausea at the 1.75 mg dose - it is the predictable consequence of hitting MC4R centrally.
Keep the lyophilised powder frozen at −20 °C. After reconstitution with bacteriostatic water, refrigerate at 1-6 °C and protect from light. The cyclic structure gives PT-141 good stability in solution within the normal peptide-handling window.
No, and no. This article is educational only. We do not provide dosing, medical recommendations, or health claims. Our products are sold strictly for laboratory research, not for personal use of any kind.
Open the shop listing via “View product details.” There you will see batch specs, the Certificate of Analysis (COA), concentration, purity grade, and available SKUs with current pricing.
Other compounds researchers often read about alongside PT-141.
Primary literature and registries for PT-141, plus mainstream coverage of the peptide category. Research use only - not medical advice.
Databases & literature:
Peptides in the news:
Access concentration, batch info, variants, and current pricing on our shop.
Also known as: PT-141, Bremelanotide, Vyleesi, Bremelanotide Acetate, MC4R Agonist, Cyclic MSH Analogue, Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-OH